• Palomid 529 (P529): Optimizing PI3K/Akt/mTOR Pathway Inhibit

  2026-05-20

  Palomid 529 (P529) delivers potent, dual mTORC1/mTORC2 inhibition for cancer and neuroscience research, uniquely enhancing experimental control over PI3K/Akt/mTOR-driven phenotypes. This article breaks down actionable protocols, troubleshooting strategies, and practical insights for maximizing data reproducibility and translational relevance.

• Maraviroc (UK-427857): Optimizing HIV and Stroke Research Wo

  2026-05-20

  Maraviroc stands out as a selective CCR5 antagonist for precise HIV-1 entry inhibition and neuroinflammation modulation. This guide translates benchmark studies and advanced protocols into actionable workflows, helping researchers troubleshoot and maximize the reliability of results in both virology and stroke inflammation models.

• FPH1 (BRD-6125): Enabling Advanced Hepatocyte Proliferation

  2026-05-19

  Discover how FPH1 (BRD-6125) revolutionizes hepatocyte proliferation assays and iPS cell-derived hepatocyte workflows. This article offers a unique, in-depth analysis of FPH1's mechanistic impact and its integration with state-of-the-art gene regulation strategies.

• Taltirelin Acetate: Protocols, Innovations, and Troubleshoot

  2026-05-19

  Taltirelin acetate stands out as a long-acting TRH analog, enabling sustained and selective neuroprotection in Parkinson's disease and sleep disorder models. This article delivers actionable protocols, experimental insights, and troubleshooting strategies to maximize reproducibility and research impact with APExBIO's Taltirelin acetate.

• Cytotoxic Effects of NSAIDs on Canine Osteosarcoma Cells: In

  2026-05-18

  The referenced study investigates the in vitro cytotoxicity of deracoxib and piroxicam against canine osteosarcoma cell lines, revealing that deracoxib achieves 50% inhibition of cell viability at notably lower concentrations compared to piroxicam and exerts minimal toxicity on fibroblasts. These findings refine understanding of NSAID mechanisms in bone tumor models and inform the design of future antiproliferative and bone resorption research.

• Repurposing Natural Compounds Against SARS-CoV-2: Docking In

  2026-05-18

  This study employed molecular docking and dynamics simulations to systematically assess natural vitamins for inhibitory activity against the SARS-CoV-2 main protease (3CLpro) and spike protein RBD. The findings highlight several vitamins as potential repurposed agents, providing new directions for antiviral therapeutics research targeting coronavirus infection pathways.

• Foretinib (GSK1363089): Multikinase Inhibition in Cancer Res

  2026-05-17

  Foretinib (GSK1363089) is a potent ATP-competitive inhibitor targeting multiple tyrosine kinases, notably Met and VEGFR2, with low nanomolar efficacy. It robustly blocks tumor cell proliferation and migration in vitro and reduces metastatic burden in xenograft cancer models. These characteristics make Foretinib a benchmark tool for dissecting tumor cell growth inhibition and metastasis in preclinical research.

• WAY-100635: Elevating 5-HT1A Antagonist Research in Translat

  2026-05-16

  This thought-leadership article provides translational researchers with a mechanistic and strategic roadmap for leveraging WAY-100635—N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide—in advanced neuroscience and pain research. By integrating recent insights on cannabinoid-serotonin interplay in orofacial pain models, it demonstrates how precise serotonin receptor antagonism, powered by APExBIO's WAY-100635, can refine both preclinical behavioral assays and translational strategy. The article further contextualizes existing protocol guides and highlights how this synthesis sets a new benchmark for bridging molecular pharmacology with multidimensional pain research.

• Tacalcitol Monohydrate: Synthetic Vitamin D3 for NGF and Can

  2026-05-15

  Tacalcitol monohydrate, a synthetic analog of vitamin D3, excels in both dermatological and oncology research by reliably inducing nerve growth factor and enhancing the efficacy of anticancer agents like 5-fluorouracil. This article translates bench findings into executable workflows, providing protocol parameters and troubleshooting insights for reproducible, high-impact results.

• Rottlerin (SKU B6803): Reliable PKC Inhibition for Cell Assa

  2026-05-15

  This article delivers a scenario-driven, evidence-based guide for scientists seeking reproducible cell viability and apoptosis assays using Rottlerin (SKU B6803). It explores real laboratory challenges, protocol optimization, and vendor selection—demonstrating why APExBIO’s Rottlerin is a robust PKC inhibitor for research workflows.

• Ribonuclease R (20 U/μL): Powering Circular RNA Enrichment

  2026-05-14

  Ribonuclease R (RNase R) (20 U/μL) from APExBIO empowers researchers to selectively degrade linear RNA, enabling precise circular RNA enrichment and advanced RNA structure-function studies. This article outlines optimized workflows, troubleshooting tactics, and experimental strategies to maximize the scientific impact and reliability of RNase R in cutting-edge RNA research.

• LY2603618: Redefining Chk1 Inhibition in Genome Stability an

  2026-05-14

  This thought-leadership article advances the understanding of LY2603618, a highly selective Chk1 inhibitor, by integrating new mechanistic insights—especially the interplay between DNA damage response, nuclear cGAS, and cell cycle checkpoints. Drawing from recent landmark studies, it provides translational researchers with strategic guidance for experimental design, combination therapies, and workflow optimization in cancer models, particularly non-small cell lung cancer and p53-mutant tumors. The discussion transcends standard product narratives, positioning APExBIO’s LY2603618 at the forefront of DDR research and next-generation therapeutic strategies.

• Mitochondrial Permeability Transition Pore Assay Kit: Optimi

  2026-05-13

  The Mitochondrial Permeability Transition Pore Assay Kit empowers researchers with sensitive, quantitative detection of mitochondrial pore opening in live cells. By leveraging the Calcein AM fluorescent probe, it streamlines advanced mitochondrial membrane permeability assays for applications ranging from fibrosis models to apoptosis and necrosis studies.

• Trelagliptin Stimulates Osteoblast Differentiation via AMPK–

  2026-05-13

  This study demonstrates that Trelagliptin succinate (SYR-472 succinate), a long-acting DPP-4 inhibitor known for type 2 diabetes treatment, directly enhances osteoblastic differentiation via AMPK-dependent upregulation of RUNX2 in MC3T3-E1 cells. The findings suggest a mechanistic bridge between metabolic regulation and bone biology, with implications for future osteoporosis research.

• HBsAg Hijacks TBK1: Suppression of Interferon and Induction

  2026-05-12

  This study uncovers a novel mechanism by which hepatitis B surface antigen (HBsAg) manipulates TANK-binding kinase 1 (TBK1) to inhibit type I interferon production and induce early autophagy. The research provides mechanistic insight into HBV immune evasion and highlights experimental approaches for dissecting host-pathogen interactions.

16300 records 1/1087 page Next 12345 下5页 Last page